Clofarabine
Clofarabine[edit]
Clofarabine is a purine nucleoside antimetabolite used in the treatment of certain types of cancer, particularly acute lymphoblastic leukemia (ALL) in pediatric patients. It is a second-generation nucleoside analog designed to overcome the limitations of earlier drugs such as cladribine and fludarabine.
Mechanism of Action[edit]
Clofarabine works by inhibiting DNA synthesis in rapidly dividing cells. It is phosphorylated intracellularly to its active triphosphate form, which then competes with deoxyadenosine triphosphate (dATP) for incorporation into DNA. This incorporation leads to chain termination and apoptosis of the cancer cells. Additionally, clofarabine inhibits ribonucleotide reductase, further depleting the pool of deoxynucleotides necessary for DNA synthesis.
Clinical Use[edit]
Clofarabine is primarily used in the treatment of pediatric patients with relapsed or refractory acute lymphoblastic leukemia. It is administered intravenously and is often used in combination with other chemotherapeutic agents. The drug has shown efficacy in inducing remission in patients who have not responded to other treatments.
Side Effects[edit]
Common side effects of clofarabine include myelosuppression, which can lead to neutropenia, anemia, and thrombocytopenia. Other side effects may include nausea, vomiting, diarrhea, and hepatotoxicity. Due to its immunosuppressive effects, patients receiving clofarabine are at increased risk of infections.
Pharmacokinetics[edit]
Clofarabine is rapidly absorbed and distributed throughout the body after intravenous administration. It is metabolized in the liver and excreted primarily in the urine. The drug has a half-life of approximately 5 hours, allowing for daily dosing during treatment cycles.
Development and Approval[edit]
Clofarabine was developed to improve upon the efficacy and safety profile of earlier nucleoside analogs. It was approved by the Food and Drug Administration (FDA) in 2004 for the treatment of pediatric acute lymphoblastic leukemia. Since its approval, clofarabine has been studied in various clinical trials to explore its potential use in other hematologic malignancies and solid tumors.
